Last reviewed · How we verify
TIGILANOL TIGLATE
At a glance
| Generic name | TIGILANOL TIGLATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma (PHASE2)
- A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer (PHASE2)
- A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma (PHASE2)
- A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIGILANOL TIGLATE CI brief — competitive landscape report
- TIGILANOL TIGLATE updates RSS · CI watch RSS